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Abstract  
 
Background: Many asthmatics remain sub-optimally controlled despite current 
treatments. Reasons include comorbidities that could aggravate asthma, including 
gastro-esophageal reflux (GER). We aimed to investigate whether aspiration occurs in 
asthmatic patients and if so does it correlate with asthma control.  
 
Methods: Patients had ACQ-7, FeNO, and spirometry performed to characterize their 
level of asthma control.  Barium swallow with provocation was performed to assess 
for predisposition to aspiration. Patients underwent bronchoscopic investigation, with 
bronchoalveolar lavage (BAL) pepsin measured as a marker of aspiration.  
 
Results: Seventy-eight patients stratified by disease severity (GINA) into mild 
(35.8%), moderate (21.7%) and severe (42.3%) were studied. Pepsin was detectable 
in BAL in 46/78 (58.9%).  There were no differences between pepsin levels in 
patients with different disease severity. Furthermore, no significant associations were 
seen between pepsin level and measures of asthma control, FEV1, ACQ or 
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exacerbation frequency. Similarly no associations were found with adjustments for 
smoking history, BMI, proton pump inhibitor use, eosinophil count or IgE.  When 
stratified into eosinophilic or neutrophilic asthmatic populations based on BAL there 
was no relationship to detected pepsin concentrations.  A positive barium swallow 
(seen in 33/60 patients) did not correlate with BAL pepsin level and we found no 
significant association between barium swallow result and ACQ, GINA, exacerbation 
frequency or FEV1 using either univariate or multivariate analyses.   
 
Conclusion: Our study suggests that the importance of aspiration on current asthma 
symptom control and exacerbation rate may be over-stated. However, our study did 
not address the role of aspiration and future risk of exacerbation. 
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INTRODUCTION   
 
Approximately 10% of patients with asthma have persisting symptoms and 
exacerbations despite combination therapy with long-acting β agonists and inhaled 
corticosteroids1. This inadequate therapeutic response may be due to medication-
refractory asthma or to difficult-to-manage asthma arising from confounding issues 
such as poor inhaler technique, poor adherence or coexisting comorbid disease1-3. 
Adherence to medication may be compounded by the fact that some patients may 
demonstrate a reasonable inhaler technique when directly observed, but may be 
careless in their inhaler use on a day-to-day basis4-6. Comorbidities and complicating 
conditions such as rhinosinusitis, gastroesophageal reflux (GER) and obesity also play 
significant roles in uncontrolled asthma1.   
 
Several risk factors have been identified with a more severe asthma phenotype.  These 
include female sex, obesity, and tobacco exposure, some of which are also risk factors 
for GER7. Previous studies suggest that GER, although often asymptomatic, is 
common in the asthmatic population8, but it is unclear whether any association 
between GER and asthma severity is the result of confounding or due to a direct 
independent effect.  Trials examining the potential therapeutic use of proton pump 
inhibitors (PPI’s) in asthma have had mixed results9-11. Therefore, current evidence 
does not support their routine use to improve clinical outcomes in asthma. However, 
while GER may predispose to aspiration it is not synonymous with it. In addition, 
treatment with PPI’s reduces gastric acidity and thus acidity of reflux, but does not 
prevent non-acid reflux, or aspiration into the airways of at risk patients12. If such 
non-acid reflux is mechanistically important then PPI’s would be expected to be of 
limited efficacy.  
 
Pepsin is produced in the stomach in response to substances such as CCK, gastrin, 
VIP, secretin and insulin. Levels of pepsin, used as a biomarker of gastric aspiration, 
are elevated in BAL of lung transplant recipients, and are associated with acute and 
chronic rejection14. Fundoplication, which reduces or prevents aspiration has been 
successfully employed post-lung transplant in uncontrolled studies.  Successful 
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fundoplication has also been reported in asthmatic patients, albeit in case reports and 
series15.  
 
The aim of this study was to determine the prevalence of aspiration (as defined by 
detectable pepsin in BAL) in a cohort of patients with mild, moderate and severe 
asthma.   The association of BAL differential, smoking status, steroid use (oral as well 
as inhaled), PPI use, BMI as well as the presence of atopy, with pepsin level was also 
examined. 
 
METHODS  
Study approval was granted by the University College Cork’s clinical research ethics 
committee: (ECM 4 (m) 01/10/13).  After informed consent was received, 78 
asthmatics were prospectively recruited from an asthma clinic in Cork University 
Hospital.  On the morning of bronchoscopy, spirometry and a validated asthma 
control questionnaire (ACQ-7) were completed by enrolled subjects16. A history of 
exacerbations over the preceding 12-month period was ascertained and validated 
against both inpatient and community pharmacy prescriptions. Patients had blood 
drawn for peripheral eosinophil count, IgE and RAST testing for grass pollen, animal 
danders, house dust mite, and aspergillus. Finally testing of FeNO was performed 
using the NIOX MINO® device (Aerocrine AB, Sweden)17. 
 
Bronchoscopy and BAL:  
Bronchoscopy was performed under conscious sedation with patients in a semi 
reclined position. 
 
BAL was obtained  from the right middle lobe or lingula as a standardized 3 x 60 ml 
procedure. BAL pH was measured using non-bleeding pH indicator strips 
immediately post-bronchoscopy (Merck, Germany). The BAL sample was divided, 
and clinical microbiology was assessed in a standardized fashion.  Differential cell 
counts were made on Kwik Diff™ stain (Thermo Scientific, USA) cyto-centrifuge 
preparations. Cell-free BAL supernatants were prepared by centrifugation (10 min, 
500g, 21°C); aliquots were subsequently stored at -80°C before ELISA testing.  
 
Pepsin ELISA  
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A locally developed indirect ELISA was used to measure pepsin13. Briefly, 100 µL of 
pepsin standard (pepsin from porcine gastric mucosa, Sigma) and undiluted BAL 
supernatants were allowed to adsorb onto a 96-well plate (Nunc MaxiSorp) in 
triplicate. Non-specific binding sites were blocked with 1% ELISA grade bovine 
serum albumin (Merck Millipore) in PBS (pH 7.4). The primary antibody was 
specific to porcine pepsin (Biodesign International Cat no W59117G). Secondary 
antibody was horse radish peroxidase-conjugated rabbit, anti-goat (Sigma). 
Antibodies were diluted in Tris-buffered saline (20 mM Triza base, 150 mM NaCl, 
pH 7.4) containing 0.1% BSA and 0.05% Tween 20. The substrate used was 2,2’-
Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) and the reaction was stopped with 
an equal volume of 1% SDS. Negative controls were performed with the omission of 
primary antibody.  
 
Barium Swallow 
A standard double-contrast barium swallow study was carried out with patients in 
both upright and supine positions. Where spontaneous GER was not demonstrated, 
provocation manoeuvres were employed, starting with a cough, followed by Valsalva 
manoeuvres, rolling the patient and the water siphon test. Secondary signs of reflux 
were recorded, including esophageal reflux, cricopharyngeal bars and hiatal herniae 
but only patients in whom reflux was demonstrated during the procedure were 
characterised as positive for GER18. 
 
 
Statistics: 
The distribution, central tendency and spread of each variable were examined using 
standard tabular and graphical methods. In primary analysis the association of 
aspiration with markers of disease severity was examined in univariate analysis using 
Fishers exact test and in multivariate analysis using logistic regression. Analysis was 
conducted using GraphPad Prism 6 (La Jolla California USA). 
RESULTS: 
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Patient characteristics are described in Table 1. Seventy-eight patients were recruited 
(49 female).  There were 8 current (14.8 pack years), 19 ex-smokers (15 pack years) 
and 51 non-smokers. There were no significant differences in smoking status across 
disease severity.  
Thirty-two patients demonstrated positive barium studies.  Twenty-six patients were 
on PPI’s and/or H2-antagonist therapy.  Eight patients were on maintenance regimens 
of oral steroids at the time of testing (range 5-20mg daily). In total 63 patients 
underwent all investigations, with a further 15 patients undergoing all investigations 
except barium swallow. 
 
Pepsin levels: 
BAL pepsin was detectable in 46/78 (58.9%) patients. Peripheral eosinophilia 
(>0.3x109/ml) was present in 26/78 (33.3%), with an elevated IgE (>80UI/ml) 
detected in 42/78 (53.8%) of patients. BAL cell differential demonstrated eosinophilia 
(>1%) in 28/78 (35.9%), and neutrophilia (>3%) in 27/78 (34.6%) (see Supplemental 
Figure 1)19.  A significant correlation was seen between peripheral and BAL 
eosinophils, r= 0.39 (p < 0.0005). 
 
There was no association between detectable pepsin and disease severity, asthma 
control, exacerbation frequency or FEV1 (Fig. A). Similar results were found when 
the model was further adjusted for smoking history, BMI, PPI use (Fig B), eosinophil 
and neutrophil counts and serum IgE.  BAL pH also had no significant association 
with disease severity (Figure C). 
 
There was no significant difference between barium study result and BAL pepsin; 
mean (sd) pepsin for positive study 3.4 (1.3) vs. 3.8 (1.4) ng/ml for negative study, p= 
non-significance (Fig D). When the cohort was divided into positive/negative barium 
swallow, there was no association between positive barium swallow and ACQ, 
asthma severity, exacerbation frequency or FEV1 on either univariate or multivariate 
analyses.  
 
In a simultaneous multivariable linear regression model, ACQ scores were 
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significantly related to oral corticosteroid use (β=1.2, p=0.006), inhaled corticosteroid 
use (β =0.83, p<0.001), but not detectable BAL pepsin (β =0.004, p=0.99).  
 
 
DISCUSSION: 
Research to date, pertaining to the possible utility of BAL pepsin as a marker of 
aspiration has been undertaken mainly in the areas of acute lung injury, end-stage 
lung disease, and post lung transplantation13,14,23.  It has been shown that detection of 
pepsin and bile acids in BAL and exhaled breath condensate can be employed to aid 
identification of lung transplantation recipients with GER-induced aspiration.  
Elevated levels are associated with acute allograft rejection and/or bronchiolitis 
obliterans syndrome13.  The use of pepsin as a surrogate for aspiration and therefore 
increased risk of rejection has led to its use as a means for justifying anti-reflux 
surgery in this niche population, with clinical outcomes suggesting a protective role in 
terms of non-allogenic injury20.   
It has long been postulated that there is a link between GER and asthma severity7. 
Despite this there has been a paucity of research specifically looking at airway pepsin 
as a biomarker of adverse clinical outcome and disease severity in the asthmatic lung.  
Our results demonstrated a median pepsin concentration of 3.58ng/ml (range 2.53-
15.78ng/ml), in the 58.9% of patients demonstrating detectable pepsin, confirming 
that aspiration does occur in asthmatic patients. Despite its demonstrable presence, 
pepsin concentration showed no significant association with clinical markers of 
disease severity or asthma control. 
Asthma and GER are known to share potential risk factors, such as smoking and 
obesity.  BAL pepsin levels demonstrated no association with either BMI or smoking 
history.  More importantly, there was no significant difference in pepsin levels when 
divided according to the presence or absence of GER by barium swallow. 
The median pepsin concentration of 3.58ng/ml, when compared to findings in other 
studies (using similar BAL sampling techniques), was significantly greater than 
control groups (median 1.1ng/ml), and patients with chronic cough (median 0ng/ml). 
This was therefore consistent with the presence of micro-aspiration into the lungs of 
some asthmatics13.  The levels are below those seen post lung transplantation (median 
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8.3ng/ml), which is not surprising as lung allograft recipients are regarded as being 
especially vulnerable to aspiration because of gastroparesis, impaired cough21, and 
dysfunctional mucociliary clearance22.    
Pepsin levels however did not exhibit a significant correlation with asthma 
exacerbation frequency (p=0.66).  When patients were subdivided into groups by 
exacerbation frequency (≤3, 4-6 and ≥7 exacerbations/year) there was no significant 
difference in pepsin concentration across the groups (3.27ng/ml, 2.53ng/ml and 
3.51ng/ml respectively). There remains the possibility that low-grade exposure to 
aspiration over a prolonged period of time may still play a role in promoting airway 
inflammation and increase the risk of future exacerbation, but our study does not 
suggest that this is associated with poorer asthma control.   
Pepsin levels were not significantly different in patients treated with maintenance acid 
suppression therapy (median, 2.85ng/ml) compared with patients who were untreated 
(median, 2.79ng/ml p =ns). This provides evidence of gastric aspiration even in 
patients who were treated with maintenance PPI’s. Similar results have been 
previously reported in the post-transplant population14. This may partially explain 
why trials examining the potential use of PPI’s in asthma have afforded mixed 
results9-11,23.  
 
In this study we utilized pepsin and barium swallow (with provocation), rather than 
pH manometry/24hr impedance to assess reflux. Barium swallow (esophagography) 
maintains a role in the modern assessment of GERD, especially in patients with 
symptoms severe enough to warrant the consideration of surgical intervention24-28. 
Despite it’s many limitations, a recent consensus statement from the Society of 
Abdominal Radiology has recommended that due to its inexpensive and non-invasive 
nature, in conjunction with its wide availability, that Barium swallow should be 
considered as a first-line test for the investigation of GERD29. While the sensitivity of 
the standard barium swallow for the detection of reflux is often quoted as low as 35-
50%30, with the addition of provocative manoeuvres the sensitivity of barium swallow 
approaches that of pH testing31,32.    As we were more interested in the role of 
aspiration, (be it acidic or non-acidic refluxate) we felt that barium swallow (at the 
time of initial study planning and approval) was an appropriate means to assess for 
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reflux with the presence of BAL pepsin ultimately defining the presence of aspiration.  
Our results demonstrated however, no significant relationship between barium 
swallow and either pepsin concentration or exacerbation frequency, thereby 
suggesting that Barium swallow did not accurately reflect the presence of aspiration 
in our cohort. Although we did not assess for noctural reflux symptoms, across the 
entire asthma disease severity there was no observable relationship to the presence of 
aspiration or the treatment effect of PPI.  Furthermore, our study would undoubtedly 
have been strengthened by performing pH manometry/24hr impedance in our patients 
and exploring whether or not this test reflects BAL pepsin levels. 
 
Further studies have looked at the effect of PPIs on acidic bile salts as opposed to 
pepsin.  Hou et al demonstrated in an epithelial cell model that omeprazole inhibits 
IL-8 secretion stimulated by exposure to acid and bile salts33.  They demonstrated that 
acidic bile salts activate the IL-8 promoter through NF-KB and AP-1 DNA binding 
sites, and that omeprazole inhibits IL-8 production by blocking nuclear translocation 
of p65, as well as decreased binding of p65, c-jun and c-fos to the IL-8 promoter.  
These effects occurred independently of the effects on gastric acid secretion, 
demonstrating a novel mechanism that might contribute to the beneficial effects of 
PPIs in the treatment of reflux related pulmonary inflammation.   The caveat to this 
finding comes from research published by Pauwels et al, in which they examined the 
effect of gastric aspirates from CF patients being treated with a PPI and found that 
such aspirates demonstrated an enhanced inflammatory effect (higher IL-8 
production) on CF bronchial epithelial cells34. We have recently shown that 
microbiological growth from gastric juice occurred when gastric juice pH was >4 and 
that gastric and airway microbiomes of people with CF who reflux are similar, 
indicating a possible mechanism to explain such observations35,36. As chronic PPI 
treatment in CF may result in a paradoxically proinflammatory effect in airways, 
alternative anti-reflux therapies may need to be considered. 
 
Our study has several possible limitations. Having only 17% of our patients 
designated GINA 5, limits the strengths of our conclusions.  Furthermore, we did not 
assess another commonly cited asthma outcome measure; bronchial hyper-reactivity.  
This would undoubtedly have been of interest, and would have enhanced our findings.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
There also exists a plausible alternative mechanism for reflux-mediated exacerbation 
of asthma in the form of vagally mediated, reflexive bronchospasm. Acidic-
stimulation of esophageal mucosal receptors giving rise to vagally mediated reflex 
bronchospasm. Mansfield and colleagues noted that the total respiratory resistance 
increased by 10% in asthmatics with a positive Bernstein test (acid perfusion test) 
after esophageal acid stimulation37.  Wright and colleagues noted significant 
decreased airflow and arterial oxygen saturation before and after esophageal acid 
perfusion38. Atropine pretreatment abolished these findings, providing evidence for an 
acid-induced vagally mediated esophagobronchial reflex.  Therefore, although our 
results show definitive aspiration (as denoted by the presence of pepsin in the BAL of 
our cohort); the possibility remains for worsening of asthma symptoms without 
aspiration into the lungs, but simply into the esophagus, potentially via this alternative 
mechanism.  
 
We have demonstrated that pepsin, and therefore aspiration occurs in the asthmatic 
lung.  However, there does not seem to be a clear link between its presence and 
disease severity.  It may be that in asthmatics, pepsin in itself is not an accurate 
biomarker of the inflammatory airway process that results from exposure to chronic 
aspiration. Alternatively, it may be that chronic exposure over time to low levels of 
aspirate is sufficient to drive an inflammatory response causing subsequent 
differences in clinical severity. Further studies at cellular level are needed to examine 
the underlying pathways involved and ascertain whether the presence of pepsin is 
indeed a marker of a pro-inflammatory state. However, based on the lack of clearly 
demonstrable difference between pepsin levels in patients with differing asthma 
severity, it may ultimately be that the impact of aspiration on disease severity at a 
clinical level has been over stated. 
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TABLE 1. PATIENT CHARACTERISTICS 
                   (Mean ± Standard deviation) 
 
 
 N= ACQ-
7 
score 
FEV1 
(%predicted) 
Blood 
Eosinophil 
count(109/ml)  
BMI 
(kg/m2) 
pH Pepsin 
(ng/ml) 
FeNO 
(ppb) 
Exacerbations/
year 
GINA 
1 
11 1.2
(0.7) 
80.9 
(10.8) 
0.22 
(0.22) 
26.16 
(5.33) 
6.16 
(0.30) 
5.88 
(4.14) 
37.8 
(32.1) 
2.18 
(1.72) 
GINA 
2 
17 1.1 
(0.6) 
90.0 
(13.6) 
0.29 
(0.23) 
25.76 
(3.91) 
6.22 
(0.20) 
4.68 
(1.55) 
30.2 
(23.5) 
3.00 
(3.92) 
GINA 
3 
17 1.9 
(1.0) 
86.7 
(20.6) 
0.33 
(0.39) 
27.54 
(6.87) 
6.16 
(0.34) 
   4.45 
  (1.61) 
24.1 
(10.6) 
3.63 
(2.36) 
GINA 
4 
20 2.7 
(0.7) 
75.5 
(17.1) 
0.20 
(0.17) 
29.61 
(6.45) 
6.23 
(0.37) 
4.43 
(1.39) 
20.2 
(14.3) 
4.75 
(3.65) 
GINA 
5 
13 4.2 
(1.1) 
47.7 
(20.2) 
0.35 
(0.32) 
31.13 
(6.16) 
6.33 
(0.44) 
4.02 
(1.52) 
32.1 
(43.4) 
8.23 
(4.60) 
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Abbreviation List 
 
BAL: bronchoalveolar lavage 
BMI: body mass index 
FeNO: fractional exhaled nitric oxide 
FEV1: forced expiratory volume in one second 
GER: gastro-esophageal reflux 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
 
 
e-Figure 1. BAL Immune cell profile of asthmatic patient cohort. n= 78. 
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